ClinicalTrials.gg
Status unknownNCT01141933Updated Mar 6, 2018

Creating Meaning Following Cancer: An Intervention to Improve Existential and Global Quality of Life

An interventional study of Cognitive-existential intervention and Usual care in Non-metastatic Cancer and Adjustment Disorder, sponsored by CHU de Quebec-Universite Laval. Status unknown at 6 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-06.

Sponsored by CHU de Quebec-Universite Laval · Not applicable, Interventional, and Supportive care

The sponsor has not verified this record recently (last verified Mar 2018), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
513
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to test the efficacy of a cognitive-existential intervention (using either an individual or a group format) to improve the existential and global quality of life of patients as compared to usual care in a population of adult non-metastatic cancer patients.

Read the detailed description

People diagnosed with cancer must learn to cope with loss of meaning and empowerment which compromises quality of life. Questions regarding "Why me?", along with universal existential concerns about death, search for meaning, and sense of control over one's life, often constitute the principal source of overall suffering. Since there is no single and identifiable cause for cancer, those existential questions are commonly observed among patients who demand specific interventions to properly address this central issue. The existential approach can be used to help patients find meaning in the midst of a crisis. It addresses a central issue of survivorship in cancer.

The conceptual model explains the relation between being exposed to a stressful and traumatic life event such as cancer and the risk of progressing toward adjustment difficulties which compromises quality of life and existential integrity. Cancer constitutes a major stressor involving significant losses that confronts the person's beliefs system. A set of therapeutic strategies can help to cope with this inevitable challenge: 1) cognitive-behavioral strategies; 2) direct existential intervention; and 3) social support through supportive-expressive strategies. Adjustment first involves cognitive reframing of the perception of the situation (situational meaning). Cognitive reframing also contributes to a readjustment of personal beliefs and values (global meaning and existential dimension). Existential strategies enable to further this process by including cognitive (beliefs, sense of coherence, expectations), motivational (choice, goal setting, and goal driving) and affective dimensions. The expressive-supportive strategy promotes active listening and non-judgmental support to encourage expression of emotions. The use of these active coping strategies (meaning-based) to the threatened-life challenge enables optimization of existential and global quality of life, as opposed to employing passive strategies such as avoidance.

02

Conditions studied

  • Non-metastatic Cancer
  • Adjustment Disorder

Keywords

  • Creating meaning
  • Therapy
  • Cancer
  • Oncology
  • Existential
  • Spirituality
  • Quality of life
  • QOL
  • Psycho-oncology
  • French-canadian
  • Cognitive therapy
  • Existentialism
03

In context

Adjustment Disorders

63 studies on the registry are indexed under Adjustment Disorders; 13 are open to participants now.

This study's planned enrollment of 513 is above the median of 100 across 52 interventional studies indexed under Adjustment Disorders.

Browse Adjustment Disorders studies →

Lead sponsor

CHU de Quebec-Universite Laval is the lead sponsor of 137 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be of 18 years of age or more;
  • Speak French;
  • Have received a diagnosis of non- cancer;
  • Be available to participate in the program of 12 weekly group or individual sessions.

Exclusion criteria

Exclusion Criteria:

  • Depressive mood (score greater than 10 on the Hospital Anxiety and Depression Scale depressive subscale) that could interfere with the intervention. Since we specifically target the existential dimension and it might temporarily provoke questioning in patients, high psychological distress must first be addressed using other approaches.
  • Diagnosis of cancer or diagnosis of non-metastatic cancer with a usually fast-growing and unpredictable course, making it unlikely to adhere to the intervention (e.g., pancreatic cancer, acute leukemia, glioblastoma).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
513 participants (estimated)

Study arms

  • Other
    Usual care

    Subjects in this group receive the usual treatment only.

    Other: Usual care

  • Experimental
    Individual intervention

    Consisting in a 12 weekly sessions with a therapist. Each session lasts 1 hour.

    Other: Cognitive-existential intervention

  • Experimental
    Group intervention

    Consisting in a 12 weekly sessions with two therapists. Number of subjects in each group is from 5 to 10. Each session lasts 2 hours.

    Other: Cognitive-existential intervention

Interventions

  • OtherCognitive-existential intervention

    Over the past 2 years we developed a 12-week cognitive-existential intervention consisting of 12 modules. The first three modules essentially involve cognitive and behavioral techniques proposing reinforcement of the use of active behavioral (e.g., relaxation, activation) and emotional (cognitive reframing) strategies. This content comes from classical cognitive-behavioral techniques. The next 3 modules, inspired by empirically-tested interventions further explore emotional strategies. The last six modules specifically address the existential dimension. They are adapted from logotherapy techniques, which are also empirically-based, and have been adapted to a French-Canadian culture by our team. They aim to improve meaning-based and emotional coping strategies.

  • OtherUsual care

    This group receive the usual treatment only.

06

What researchers measure

Primary outcomes

  1. Existential quality of life

    At every time frame, we use two questionnaires to measure the primary outcome: 1. The McGill Quality of Life Questionnaire (MQOL): 16 items plus a single-item global scale. 2. Spiritual well-being (FACIT-SP): The FACIT-SP is a sub-scale of the FACT-G (Functional Assessment of Cancer Therapy-General) and a French version of the "FACIT-SP, FACIT-Spiritual well-being scale". This questionnaire has two sub-scales: Meaning/Peace (8 items) and Faith (4 items).

    Time frame: T0: Pre-intervention

  2. Existential quality of life

    Time frame: T1: Mid-intervention (6 weeks after the beginning of the intervention)

  3. Existential quality of life

    Time frame: T2: End of the intervention (12 weeks after the beginning of the intervention)

  4. Existential quality of life

    Time frame: T3: First follow-up measure (3 months after the end of the intervention)

  5. Existential quality of life

    Time frame: T4: Second follow-up measure (6 months after the end of the intervention)

  6. Existential quality of life

    Time frame: T5: Last follow-up measure (12 months after the end of the intervention)

Secondary outcomes

  1. Global quality of life

    To measure the secondary outcome, The McGill Quality of Life Questionnaire (MQOL) is use at every time frames.

    Time frame: T0: Pre-intervention

  2. Global quality of life

    Time frame: T1: Mid-intervention (6 weeks after the beginning of the intervention)

  3. Global quality of life

    Time frame: T2: End of the intervention (12 weeks after the beginning of the intervention)

  4. Global quality of life

    Time frame: T3: First follow-up measure (3 months after the end of the intervention)

  5. Global quality of life

    Time frame: T4: Second follow-up measure (6 months after the end of the intervention)

  6. Global quality of life

    Time frame: T5: Last follow-up measure (12 months after the end of the intervention)

07

Study locations

6 sites
  • University of Manitoba
    Winnipeg, Manitoba R3T 2N2, Canada
  • Centre hospitalier affilié universitaire de l'Hôtel-Dieu de Lévis
    Lévis, Quebec G6V 3Z1, Canada
  • McGill University
    Montreal, Quebec H3A 2T5, Canada
  • CHU de Québec - Université Laval
    Quebec, G1R2J6, Canada
  • CHU de Québec - Université Laval
    Québec, G1S 4L8, Canada
  • Institut universitaire de cardiologie et de pneumologie de Québec
    Québec, G1V 4G5, Canada
08

References and documents

Publications

  • Gagnon, P., Fillion, L., Girard, M.La recherche de sens à la suite d'un diagnostic de cancer: une invervention pour améliorer la qualité de vie existentielle et globale.Les cahiers francophones de soins palliatifs 9 (1): 57-69, 2008.
  • Gagnon P, Fillion L, Robitaille MA, Girard M, Tardif F, Cochrane JP, Le Moignan Moreau J, Breitbart W. A cognitive-existential intervention to improve existential and global quality of life in cancer patients: A pilot study. Palliat Support Care. 2015 Aug;13(4):981-90. doi: 10.1017/S147895151400073X. Epub 2014 Jul 22. PubMed 25050872 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Dec 2013 and a completion of Aug 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2010
First posted
Jun 11, 2010
Start
Feb 2009
Primary completionActual
Dec 2013
CompletionEst.
Aug 2018
Last update
Mar 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01141933
Collaborators
Laval University, Centre de recherche en cancérologie de l'Université Laval, Canadian Cancer Society (CCS), Maison Michel-Sarrazin
Responsible party
Pierre Gagnon (MD, FRCPC, Psychiatrist, CHU de Quebec-Universite Laval) — Principal investigator
First posted
Jun 11, 2010
Start date
Feb 2009
Primary completion
Dec 2013
Completion
Aug 2018 (estimated)
Last update
Mar 6, 2018

Study contacts

Pierre Gagnon, MD, FRCPC
principal investigator · Laval University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion